Jasper Therapeutics Q3 EPS $(10.19) Misses $(4.80) Estimate, Sales $8.000M Beat $3.000M Estimate
Benzinga Newsdesk 3 days ago
NewsEarningsEarnings BeatsEarnings Misses
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(10.19) per share which missed the analyst consensus estimate of $(4.80) by 112.29 percent. This is a 68.24 percent increase over losses of $(32.08) per
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(10.19) per share which missed the analyst consensus estimate of $(4.80) by 112.29 percent. This is a 68.24 percent increase over losses of $(32.08) per share from the same period last year. The company reported quarterly sales of $8.000 million which beat the analyst consensus estimate of $3.000 million by 166.67 percent.
